Nav: Home

High-risk pulmonary embolism patients often go without most effective treatments

March 18, 2017

PHILADELPHIA -- Pulmonary embolism (PE), a blood clot in the lungs which causes shortness of breath and chest pain, is the third leading cardiovascular cause of death in the United States with more than 100, 000 lives taken each year. A typical intervention for PE patients includes anticoagulants in an effort to prevent migration of the blood clot, but the higher-risk PE population -- about 30 percent of all PE patients -- are potential candidates for catheter-directed thrombolysis (CDT) and systemic thrombolysis (ST), both of which employ "clot-busting" medications known as tissue plasminogen activator (tPA).

However, in a new study presented today at the American College of Cardiology 66th Annual Scientific Session, researchers from the Perelman School of Medicine at the University of Pennsylvania have found that the utilization rates of these potentially life-saving medications are low, particularly in the sub-group of PE patients who are critically ill.

ST is the method in which "clot-busting" medication is administered intravenously (IV) to eliminate clots throughout the bloodstream, while CDT allows the medication to be directly administered into the clot in the lungs.

"For years, ST and CDT have been available for use in patients with PE, however, there has been little research done to understand how these therapies are being utilized in the real-world," said the study's presenter Srinath Adusumalli, MD, chief cardiovascular medicine fellow in the Perelman School of Medicine at the University of Pennsylvania. "Our initial data suggest that, in fact, both ST and CDT are used infrequently to treat PE, including in young, critically ill patients who may experience the highest clinical benefit from those therapies."

Adusumalli and his colleagues performed a retrospective study in which they collected data from the OptumInsight national commercial insurance claims database and identified 100,744 patients who had been hospitalized with PE during a ten-year period (2004-2014). This is the first study of its kind to examine detailed procedural coding for pulmonary embolism therapies from a national database, allowing researchers to aggregate information from a national population rather than hospital or region-specific information. The team culled through the data and found that of the 100,744 patients hospitalized with PE, 2,175 patients received either CDT or ST - roughly two percent of all PE patients. In this same timeframe, the number of PE hospitalizations increased by 306 percent.

"Another question that emerged from these findings is whether we are adequately matching the right patients to the right therapies at the right time," said senior author Peter W. Groeneveld, MD, MS, an associate professor of Medicine, research director in the Leonard Davis Institute of Health Economics, and director of Penn's Cardiovascular Outcomes, Quality, and Evaluative Research Center. "Since there is a lack of real-world clinical effectiveness and safety data on these therapies and a resulting lack of guideline-based recommendations, substantial clinical uncertainty persists as to when and in whom to use CDT and ST."

A larger team at Penn Medicine, including those who were involved with this study, created what's called the Pulmonary Embolism Response Team -- or PERT -- which is designed to employ rapid response techniques for the treatment of PE in order to match the right patient to the right therapy at the right time.

"The purpose of PERT is to ensure that high-risk PE patients are receiving the best kind of treatment plan on the most efficient timeline in order to improve outcomes," said Jay Giri, MD, MPH, an assistant professor of Cardiovascular Medicine and founder of the PERT at the Hospital of the University of Pennsylvania. "However, it is important to state that most decisions made by PERT physicians are a matter of clinical consensus rather than being based on rigorous comparative effectiveness research. The current study re-emphasizes the clinical consequences of the dearth of data in the PE field."

While the team notes these data are clinically useful and could impact the patient care decision-making process, there is still more research needed. Co-presenter and study author Bram Geller, MD, a cardiovascular medicine fellow in the Perelman School of Medicine at the University of Pennsylvania, added, "this study is the first in a two-step research plan, in which our next phase will be to actually evaluate the safety and clinical effectiveness of CDT versus ST by exploring patient outcomes in the OptumInsight commercial insurance claims database."
-end-
Additional Penn authors on this study include Lin Yang. This study is one of the first to be supported by Penn's Cardiovascular Outcomes, Quality, and Evaluative Research Center (CAVOQER) within the Leonard Davis Institute of Health Economics. Adusumalli is supported by a National Institutes of Health T32 training grant (3T32HL007843-20S1).

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.

University of Pennsylvania School of Medicine

Related Pulmonary Embolism Articles:

SNMMI publishes appropriate use criteria for V/Q imaging in pulmonary embolism
The Society of Nuclear Medicine and Molecular Imaging has published appropriate use criteria for ventilation/perfusion (V/Q) imaging in pulmonary embolism.
Antibody is effective against radiation-induced pulmonary fibrosis
Radiation therapy of the lungs often leads to irreversible connective-tissue changes that cause functional impairments in the pulmonary tissue.
Long-term limitations imposed on patients with pulmonary embolism
A multi-centre clinical study, led by Dr. Susan Kahn at the Jewish General Hospital (JGH), determined that nearly half of the patients who suffer a pulmonary embolism (PE) -- a blood clot in the lung -- experience long term limitations to their capacity for physical activity and that this had a negative impact on their quality of life.
High-risk pulmonary embolism patients often go without most effective treatments
In a new study presented today at the American College of Cardiology 66th Annual Scientific Session, researchers from the Perelman School of Medicine at the University of Pennsylvania have found that the utilization rates of these potentially life-saving medications are low, particularly in the sub-group of PE patients who are critically ill.
Sleep apnea can contribute to recurring pulmonary embolism
Researchers have found that after the first incidence of pulmonary embolism (PE), obstructive sleep apnea increases the risk for PE recurrence.
More Pulmonary Embolism News and Pulmonary Embolism Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...